BKSW — Baikang Biological group Income Statement
0.000.00%
Last trade - 00:00Consumer DefensivesMicro Cap
Annual income statement for Baikang Biological group, fiscal year end - April 30th, USD millions except per share, conversion factor applied.
2017 April 30th | 2018 April 30th | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 14.7 | 26.8 |
| Cost of Revenue | ||
| Gross Profit | 11.6 | 20.4 |
| Selling / General / Administrative Expenses | ||
| Research And Development | ||
| Total Operating Expenses | 5.91 | 9.44 |
| Operating Profit | 8.77 | 17.3 |
| Total Net Non Operating Interest Income / Expense | ||
| Other Net Non Operating Costs | ||
| Net Income Before Taxes | 8.68 | 17.6 |
| Provision for Income Taxes | ||
| Net Income After Taxes | 7.38 | 14.9 |
| Minority Interest | ||
| Net Income Before Extraordinary Items | ||
| Net Income | 7.37 | 14.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | 7.37 | 14.9 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | 0.307 | 0.621 |
| Dividends per Share |